Rigel Pharma’s influence of shaping the future of inflammatory therapy has been highlighted again with the announcement that it has signed a $1.25 billion licensing agreement with Astra Zeneca for fostamatinib disodium. more »

A new global player in the animal health sector has been created as a result of Sanofi-Aventis exercising its option from a deal announced back in September 2009. more »

GSK continues to develop its drug discovery pipeline of products with the announcement it has formed an early stage agreement with Cellzome for its Episphere technology to develop and treat immuno-inflammatory disease. more »

We have been designing and organising specialised international partnering conferences since 1987 and in these 23 years I have seen several thousand partnering profiles, i.e. the composition with which conference registrants try to attract the interest of other registrants. more »

Novartis has agreed an exclusive option for Transgene’s targeted immunotherapy product TG4010, in return for a non-refundable fee of $10 million. more »

The development of small molecule therapies continues at pace with news that Roche is the latest company to license the Galapagos discovery platform to develop new treatments for COPD. more »

The settlement between Cordis and Boston Scientific announced in February 2010 is the second agreement between the companies following a long running dispute. The litigation started several years ago as a result of disputed patents in the field of stents. more »

Part 1 of this article described how attendees of a partnering conference react if they receive an appointment request which is not justified by their own partnering interest profile and how they measure up the requesting delegate. more »

Cephalon has once again demonstrated tremendous business acumen and expanded its range of pharmaceutical products and services within the developed and emerging markets with the acquisition of Mepha for $615.4 million. more »

Better scientific understanding of drug interactions with enzymes at the molecular level has allowed some old, ‘failed’ molecules to be used for novel purposes. more »